Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway

Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H489-96. doi: 10.1152/ajpheart.00251.2008. Epub 2008 Dec 12.

Abstract

Interleukin-10 (IL-10) is an anti-inflammatory cytokine with protective actions on the vasculature. On the other hand, endothelin (ET)-1 has potent vasoconstrictor, mitogenic, and proinflammatory activities, which have been implicated in the pathophysiology of a number of cardiovascular diseases. We hypothesized that, in a condition where ET-1 expression is upregulated, i.e., on infusion of TNF-alpha, IL-10 confers vascular protection from ET-1-induced injury. Aortic rings and first-order mesenteric arteries from male C57BL/6 (WT) and IL-10-knockout (IL-10(-/-)) mice were treated with human recombinant TNF-alpha (220 ng x kg(-1) x day(-1)) or vehicle (saline) for 14 days. TNF-alpha infusion significantly increased blood pressure in IL-10(-/-), but not WT, mice. TNF-alpha augmented vascular ET-1 mRNA expression in arteries from WT and IL-10(-/-) mice. ET type A (ET(A)) receptor expression was increased in arteries from IL-10(-/-) mice, and TNF-alpha infusion did not change vascular ET(A) receptor expression in control or IL-10(-/-) mice. Aorta and mesenteric arteries from TNF-alpha-infused IL-10(-/-) mice displayed increased contractile responses to ET-1, but not the ET type B receptor agonist IRL-1620. The ET(A) receptor antagonist atrasentan completely abolished responses to ET-1 in aorta and mesenteric vessels, whereas the ERK1/2 inhibitor PD-98059 abrogated increased contractions to ET-1 in arteries from TNF-alpha-infused IL-10(-/-) mice. Infusion of TNF-alpha, as well as knockdown of IL-10 (IL-10(-/-)), induced an increase in total and phosphorylated ERK1/2. These data demonstrate that IL-10 counteracts ET(A)-mediated vascular responses to ET-1, as well as activation of the ERK1/2 pathway.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / drug effects
  • Aorta / enzymology*
  • Atrasentan
  • Blood Pressure
  • Endothelin A Receptor Antagonists
  • Endothelin-1 / genetics
  • Endothelin-1 / metabolism*
  • Endothelins / pharmacology
  • Flavonoids / pharmacology
  • Humans
  • Infusion Pumps, Implantable
  • Interleukin-10 / deficiency
  • Interleukin-10 / genetics
  • Interleukin-10 / metabolism*
  • Male
  • Mesenteric Arteries / drug effects
  • Mesenteric Arteries / enzymology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / metabolism*
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / metabolism*
  • Peptide Fragments / pharmacology
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Pyrrolidines / pharmacology
  • RNA, Messenger / metabolism
  • Receptor, Endothelin A / metabolism
  • Receptor, Endothelin B / agonists
  • Receptor, Endothelin B / metabolism
  • Recombinant Proteins / administration & dosage
  • Signal Transduction* / drug effects
  • Time Factors
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Vasoconstriction

Substances

  • Endothelin A Receptor Antagonists
  • Endothelin-1
  • Endothelins
  • Flavonoids
  • Peptide Fragments
  • Protein Kinase Inhibitors
  • Pyrrolidines
  • RNA, Messenger
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • sovateltide
  • Interleukin-10
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Atrasentan